Latest news

MIMESIS Newsletter #4: A novel systems biology approach to develop preclinical assets

MIMESIS NEWSLETTER #4, December 2018

After two years, ENYO Pharma’s EU funded MIMESIS project was a real success and has delivered several promising new drug development starting points most significantly for RSV and ICD.

MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”.

Read more »

Participation in La Matinale Santé organized by Bpifrance

ENYO Pharma’s VP Corporate Development & Strategy Nicolas Guyon-Gellin is participating today in “La Matinale Santé” organized by Bpifrance in Paris, France. Bpifrance finances businesses – at every stage of their development – through loans, guarantees and equity investments, but also offers extra financial services. During this event, Nicolas will talk about Bpifrance’s financing and investments actions in the health sector and the role of the Large Venture Fund. This will be a great opportunity to discuss how Bpifrance is currently supporting ENYO Pharma to pursue its growth and development.

Read more »

HBV Cure Workshop 2018

Pietro Scalfaro, Chief Medical Officer of ENYO Pharma, has participated to the 5th edition of the International HBV Cure Workshop 2018 on November 7 -8 in Toronto, Canada. The HBV Cure Workshop is a scientific platform that allows to accelerate the research in finding a cure of hepatitis B. During this event, researchers and clinical experts had the opportunity to discuss current challenges regarding the disease and to present research outcomes.

Read more »

Poster presentation with Novadiscovery at the ICSB 2018

ENYO Pharma is pleased to collaborate with Novadiscovery which is presenting at the ISCB today a poster titled “A logical modelling approach to prepare and accelerate the design of ODE models: Application to bile acid metabolism”. The model of bile acids metabolism was developed in the context of a project for ENYO Pharma, where the aim was to model chronic hepatitis B virus and non-alcoholic steatohepatitis (NASH).

Read more »

Europe Ambition Day 2018

ENYO Pharma was present at the Europe Ambition Day in Lyon on October, 23rd 2018. This event, organized by the Auvergnes-Rhone-Alpes Entreprises, was opened to companies, academics and research centers in the region who wish to increase their chances of receiving funding from the European Commission. During the day, ENYO Pharma had the pleasure to participate to a panel discussion to share its success story and experience regarding the access to European fundings.

Read more »